Antimalarials in rheumatic diseases (Q37799076)

23 August 2017

1 reference

title

Antimalarials in rheumatic diseases. (English)

1 reference

23 August 2017

0 references

Tett S

1

1 reference

23 August 2017

Cutler D

series ordinal

2

1 reference

23 August 2017

Day R

series ordinal

3

1 reference

23 August 2017

publication date

1 December 1990

1 reference

Bailliere's clinical rheumatology

23 August 2017

published in

1 reference

23 August 2017

volume

4

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

467-489

1 reference

Formation of myeloid bodies in rat liver lysosomes after chloroquine administration

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Hydroxychloroquine in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

In vitro assessment of the antimalarial activity of chloroquine and its major metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

UPTAKE OF DYES AND DRUGS BY LIVING CELLS IN CULTURE.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

DNA: Reaction with Chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE (SN-7618)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Current concepts in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Ocular toxicity of antimalarial drugs. Long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

A controlled study of chloroquine as an antirheumatic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Discoid lupus erythematosus treated with plaquenil

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Commentary. Lysosomotropic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine poisoning.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Ocular effects and safety of antimalarial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Effect of Chloroquine on Morphology of Cytoplasmic Granules in Maturing Human Leukocytes—an Ultrastructural Study*

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Uptake of chloroquine by human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine and rheumatoid arthritis; a short-term controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Alkalinization of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Reactions to chloroquine observed during the treatment of various dermatologic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Disposition of chloroquine in man after single intravenous and oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine excretion following malaria prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

SUPPRESSION OF IN VITRO LYMPHOCYTE RESPONSES BY CHLOROQUINE.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

The presence of abnormal lysosomes in lymphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Amodiaquine and hydroxychloroquine in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Dosage of Antimalarial Drugs for Children with Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Clinical Study with Determination of Serum Concentrations of Chloroquine and Hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

The influence of various types of breakfast on chloroquine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Acid protease activity in Plasmodium falciparum and P. knowlesi and ghosts of their respective host red cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

In vitro binding of chloroquine to rat muscle preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Role of Lysosomes in Hepatic Accumulation of Chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Antioxidant action of antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Action of chloroquine phosphate in rheumatoid arthritis. II. Chromosome damaging effect

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Protein binding of chloroquine enantiomers and desethylchloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Enantioselective Analysis of Chloroquine and Desethylchloroquine after Oral Administration of Racemic Chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Progression of retinopathy long after cessation of chloroquine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Antimalarial drugs and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Treatment of chronic discoid lupus erythematosus with chloroquine (araten).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine diphosphate in rheumatoid arthritis. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Inhibition of leucocyte motility and prevention of immune-complex experimental colitis by hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Efficacy of antimalarials in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Immunosuppressive potential of antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Inhibition of receptor-mediated uptake of a lysosomal enzyme into fibroblasts by chloroquine, procaine and ammonia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Ocular Changes Induced by Long-Term Hydroxychloroquine (Plaquenil) Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Antibodies to denatured deoxyribonucleic acid in lupus erythematosus serum. V. Mechanism of DNA-anti-DNA inhibition by chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Bioavailability of hydroxychloroquine tablets in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Hydroxychloroquine concentrations and clinical effects in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Effect of food on bioavailability of chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine: protective and destructive effects on injured rabbit cartilage in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

The chemosuppression of chemotaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

1 reference

7 January 2021

Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

Chloroquine phosphate (Aralen) in the long-term treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980004-4

7 January 2021

10.1016/S0950-3579(05)80004-4

Identifiers

DOI

1 reference

release_gm7mbbhlybhnjpd6sg7dm7zap4

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gm7mbbhlybhnjpd6sg7dm7zap4

24 November 2022

mapped directly with Wikidata item

1 reference